Sector
PharmaceuticalsOpen
₹77.39Prev. Close
₹75.95Turnover(Lac.)
₹1.5Day's High
₹77.39Day's Low
₹74.6152 Week's High
₹94.952 Week's Low
₹25.84Book Value
₹11.94Face Value
₹10Mkt Cap (₹ Cr.)
57.42P/E
21.52EPS
3.53Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 7.42 | 7.42 | 7.42 | 7.42 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -0.31 | -0.56 | 1.11 | 0.24 |
Net Worth | 7.11 | 6.86 | 8.53 | 7.66 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 40.13 | 25.17 | 37.54 | 29.01 |
yoy growth (%) | 59.4 | -32.93 | 29.39 | 14.73 |
Raw materials | -15.24 | -9.99 | -13.9 | -10.52 |
As % of sales | 37.99 | 39.68 | 37.03 | 36.25 |
Employee costs | -15.82 | -12.96 | -15.12 | -11.92 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 0.74 | -2.53 | 0.43 | 0.32 |
Depreciation | -0.27 | -0.17 | -0.24 | -0.18 |
Tax paid | 0.12 | 0.01 | -0.15 | -0.05 |
Working capital | 2 | -0.44 | 2.46 | -5.43 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 59.4 | -32.93 | 29.39 | 14.73 |
Op profit growth | -140.37 | -505.13 | 111.34 | 304.73 |
EBIT growth | -153.58 | -394.3 | 31.98 | 65.61 |
Net profit growth | -134.61 | -1,012.54 | 1.98 | -1,928.47 |
Particulars (Rupees in Crores.) | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|
Gross Sales | 25.18 | 37.54 | 31.03 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 25.18 | 37.54 | 31.03 |
Other Operating Income | 0 | 0 | 0 |
Other Income | 0.8 | 0.29 | 0.32 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,798.6 | 156.54 | 4,31,544.39 | 863.29 | 0.75 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,210.35 | 89.74 | 1,64,865.28 | 518 | 0.48 | 2,302 | 513.62 |
Cipla Ltd CIPLA | 1,534.4 | 29.27 | 1,23,920.06 | 1,178.16 | 0.85 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,361.6 | 69.54 | 1,13,766.71 | 460 | 0.83 | 2,376 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,558.95 | 51.15 | 1,02,527.44 | 634.43 | 0 | 2,529.74 | 269.23 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
Amrutbhai P Prajapati
Independent Director
Chhayaben Ashwinbhai Shah
Independent Director
Viplav Suryakantbhai Khamar
Managing Director & CEO
Aalap Prajapati
Independent Director
Surendra Kumar Sharma
Independent Director
Navinchandra Patel
Chairman & Wholetime Director
Natwarbhai P Prajapati
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Gujarat Terce Laboratories Ltd
Summary
Gujarat Terce Laboratories Limited, incorporated in 1985, produces branded generic formulations for the domestic market. Over its more than three-decade business journey, the Company developed an extensive product basket comprising 50 brands covering multiple therapeutic areas which are marketed by its 180+ strong MR team across 13 Indian states. Headquartered in Ahmedabad, the Company has its fully automated facility at Chhatral, in Gandhinagar, Gujarat By 1986, Terce had established its presence in Gujarat and Rajasthan with a firm footing. In 1992, the management raised public equity to give concrete shape and listed the Company on Bombay Stock Exchange. In same year, Company established extensive manufacturing facility at Chhatral in Gandhinagar, Gujarat. As India heralded new leaps in the pharma sector to become a global force to reckon with by 2005, the Company closely followed the narrative with ferocious growth expanding presence in the domestic and international market.The Company is an ISO 9001 certified, WHO-GMP compliant operating facility manufactures world-class formulations and healthcare products that feature in acute and chronic therapeutic areas. It engaged into manufacture and sale of pharmaceutical formulations and ayurvedic medicines in India and internationally. It offers products in the form of tablets, capsules, syrups, and injections. The installed capacity of the Company is 270 million tablets and 108 million capsules per annum.The facility is ISO 90
Read More
The Gujarat Terce Laboratories Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹77.38 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gujarat Terce Laboratories Ltd is ₹57.42 Cr. as of 04 Dec ‘24
The PE and PB ratios of Gujarat Terce Laboratories Ltd is 21.52 and 6.36 as of 04 Dec ‘24
The 52-week high/low is the highest and lowest price at which a Gujarat Terce Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Gujarat Terce Laboratories Ltd is ₹25.84 and ₹94.9 as of 04 Dec ‘24
Gujarat Terce Laboratories Ltd's CAGR for 5 Years at 53.54%, 3 Years at 75.38%, 1 Year at 165.56%, 6 Month at 36.90%, 3 Month at 29.45% and 1 Month at -14.86%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice